Literature DB >> 18031726

Effects of selective inhibition of N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) on mice in learning and memory tasks.

Krzysztof Lukawski1, Rafał M Kamiński, Stanisław J Czuczwar.   

Abstract

The purpose of the present study was to examine the effects of 2-(phosphonomethyl)-pentanedioic acid (2-PMPA), a selective inhibitor of N-acetylated-alpha-linked-acidic dipeptidase (NAALADase, glutamate carboxypeptidase II), an enzyme catalyzing the cleavage of glutamate from the neuropeptide N-acetyl-aspartyl-glutamate (NAAG), on memory processes in mice. Long-term memory was evaluated in step-through passive avoidance task while alternation behavior, as a measure involving spatial working memory, was assessed in Y-maze task. Additionally, horizontal activity was evaluated by means of electronically monitored locomotor activity system. The mice were treated with either 2-PMPA (50, 100 and 150 mg/kg i.p.) or N-methyl-d-aspartate (NMDA) receptor antagonist, (5R,10S)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclo-hepten-5,10-imine hydrogen maleate (MK-801) at doses of: 0.05, 0.1, 0.15 and 0.2 mg/kg i.p., as a comparator. In the passive avoidance task, the drugs were administered once before or immediately after training, and before retention test. 2-PMPA at the doses used did not affect retention of passive avoidance; however, it increased the latency to enter the dark box during the training day. In the Y-maze task, 2-PMPA (150 mg/kg i.p.) impaired spontaneous alternation and reduced locomotion while the lower dose of 100 mg/kg was ineffective. In the locomotor activity test, 2-PMPA (100 and 150 mg/kg i.p.) did not significantly affect horizontal activity. MK-801 (0.2 mg/kg i.p.) injected before training reduced retention in the passive avoidance task. In the Y-maze task, MK-801 (0.1 mg/kg i.p.) impaired alternation behavior and considerably increased locomotion in the Y-maze and locomotor activity test. These results indicate that NAALADase inhibition may impair alternation behavior.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18031726     DOI: 10.1016/j.ejphar.2007.10.032

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

Review 1.  NAAG, NMDA receptor and psychosis.

Authors:  Richard Bergeron; Joseph T Coyle
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

2.  Synaptic NMDA Receptor Activation Induces Ubiquitination and Degradation of STEP61.

Authors:  Jian Xu; Pradeep Kurup; Angus C Nairn; Paul J Lombroso
Journal:  Mol Neurobiol       Date:  2017-05-02       Impact factor: 5.590

Review 3.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

4.  NAAG peptidase inhibitors and deletion of NAAG peptidase gene enhance memory in novel object recognition test.

Authors:  Karolina J Janczura; Rafal T Olszewski; Tomasz Bzdega; Dean J Bacich; Warren D Heston; Joseph H Neale
Journal:  Eur J Pharmacol       Date:  2012-11-29       Impact factor: 4.432

5.  Pharmacokinetics and pharmacodynamics of the glutamate carboxypeptidase II inhibitor 2-MPPA show prolonged alleviation of neuropathic pain through an indirect mechanism.

Authors:  James J Vornov; Krystyna M Wozniak; Ying Wu; Camilo Rojas; Rana Rais; Barbara S Slusher
Journal:  J Pharmacol Exp Ther       Date:  2013-06-17       Impact factor: 4.030

6.  NAAG Peptidase Inhibitors Act via mGluR3: Animal Models of Memory, Alzheimer's, and Ethanol Intoxication.

Authors:  Rafal T Olszewski; Karolina J Janczura; Tomasz Bzdega; Elise K Der; Faustino Venzor; Brennen O'Rourke; Timothy J Hark; Kirsten E Craddock; Shankar Balasubramanian; Charbel Moussa; Joseph H Neale
Journal:  Neurochem Res       Date:  2017-03-11       Impact factor: 3.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.